gliclazide has been researched along with perindopril in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (28.57) | 29.6817 |
| 2010's | 18 (64.29) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chalmers, J; Joshi, R; Patel, A; Perkovic, V | 1 |
| Chalmers, J; Joshi, R; Kengne, AP; Patel, A; Perkovic, V | 1 |
| Nagy, V | 1 |
| Poulter, NR | 1 |
| Cass, A; Chalmers, J; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Lisheng, L; MacMahon, S; Mancia, G; Marre, M; Neal, B; Ninomiya, T; Patel, A; Perkovic, V; Pillai, A; Poulter, N; Travert, F; Woodward, M; Zoungas, S | 1 |
| Anderson, C; Chalmers, J; Cooper, M; de Galan, BE; Dufouil, C; Grobbee, DE; Hackett, M; Hamet, P; Heller, SR; Lisheng, L; MacMahon, S; Mancia, G; Neal, B; Pan, CY; Patel, A; Pillai, A; Poulter, N; Travert, F; Woodward, M; Zoungas, S | 1 |
| Batty, GD; Chalmers, J; Czernichow, S; de Galan, BE; Hamet, P; Harrap, SB; Huxley, R; Li, Q; Neal, B; Patel, A; Poulter, N; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Heller, S; Januszewicz, A; Joshi, P; Liu, L; Neal, B; Pan, C; Patel, A; Poulter, N; Tandon, N; Woodward, M; Zoungas, S | 1 |
| Davis, SN; Konig, M; Lamos, EM; Stein, SA | 1 |
| Arima, H; Chalmers, J; Harrap, S; Hirakawa, Y; Mancia, G; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S | 1 |
| Bakris, GL; Yamout, H | 1 |
| Blomster, JI; Chalmers, J; Chow, CK; Harrap, S; Hillis, GS; Li, Q; Mancia, G; Neal, B; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S | 1 |
| Arima, H; Chalmers, J; Cooper, M; Hamet, P; Harrap, S; Hirakawa, Y; Mancia, G; Ninomiya, T; Poulter, N; Woodward, M; Zoungas, S | 1 |
| Arima, H; Billot, L; Chalmers, J; Colagiuri, S; Cooper, ME; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Hirakawa, Y; Joshi, R; Li, Q; Lisheng, L; MacMahon, S; Mancia, G; Marre, M; Matthews, DR; Mogensen, CE; Monaghan, H; Neal, B; Patel, A; Perkovic, V; Poulter, N; Rodgers, A; Williams, B; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Glasziou, P; Grobbee, DE; Hamet, P; Kengne, AP; MacMahon, S; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Cooper, M; Grobbee, R; Hirakawa, Y; Jardine, M; Kengne, AP; Matthews, DR; Patel, A; Poulter, N; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Cooper, ME; Hamet, P; Harrap, S; Heller, S; Li, Q; MacMahon, S; Mancia, G; Marre, M; Matthews, D; Neal, B; Perkovic, V; Poulter, N; Rodgers, A; Williams, B; Wong, MG; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Harrap, S; Hirakawa, Y; Lisheng, L; Mancia, G; Marre, M; Mohammedi, K; Neal, B; Rodgers, A; Williams, B; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Harrap, S; Li, Q; Marre, M; Mohammedi, K; Patel, A; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Colagiuri, S; Cooper, M; Harrap, S; Mancia, G; Marre, M; Mohammedi, K; Poulter, N; Williams, B; Woodward, M; Zoungas, S | 1 |
| Chalmers, J; Colagiuri, S; Cooper, ME; DeVries, JH; Grobbee, DE; Hamet, P; Li, Q; Mancia, G; Marre, M; van Steen, SC; Williams, B; Woodward, M | 1 |
| Chalmers, J; Cooper, ME; Hamet, P; Harrap, S; Juraschek, SP; Lazo, M; Marre, M; McEvoy, JW; Selvin, E; Wang, D; Williams, B; Woodward, M | 1 |
| Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M | 1 |
| Chalmers, J; Cooper, M; Harrap, S; Mancia, G; Ohkuma, T; Poulter, N; Tian, J; Wang, JG; Woodward, M; Zoungas, S | 1 |
2 review(s) available for gliclazide and perindopril
| Article | Year |
|---|---|
New insights from ADVANCE.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Gliclazide; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Internationality; Middle Aged; Multicenter Studies as Topic; Perindopril; Randomized Controlled Trials as Topic | 2007 |
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Gliclazide; Glycated Hemoglobin; Humans; Indapamide; Perindopril; United Kingdom | 2013 |
18 trial(s) available for gliclazide and perindopril
| Article | Year |
|---|---|
Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diuretics; Gliclazide; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Middle Aged; Multicenter Studies as Topic; Perindopril; Placebos; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2001 |
ADVANCE: breaking new ground in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Perindopril | 2006 |
[Advanced credit: patient enrolling and therapy initiation in the ADVANCE trial].
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Patient Selection; Perindopril; Research Design; Treatment Outcome | 2007 |
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Male; Microcirculation; Middle Aged; Perindopril; Placebos | 2009 |
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Erectile Dysfunction; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Perindopril; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2010 |
Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.
Topics: Aged; Asia; Australia; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Europe; Europe, Eastern; Female; Gliclazide; Glycated Hemoglobin; Humans; Indapamide; Male; Middle Aged; New Zealand; Perindopril; Proportional Hazards Models | 2011 |
Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Combinations; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Perindopril; Proportional Hazards Models | 2014 |
The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Drug Combinations; Female; Gliclazide; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Male; Myocardial Infarction; Perindopril; Retrospective Studies; Risk Reduction Behavior; Stroke | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Female; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Office Visits; Perindopril; Risk Factors | 2014 |
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Topics: Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Perindopril; Risk Factors | 2014 |
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Indapamide; Male; Perindopril; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Indapamide; Kidney Failure, Chronic; Male; Middle Aged; Perindopril; Treatment Outcome | 2016 |
Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Indapamide; Male; Middle Aged; Perindopril; Peripheral Arterial Disease; Proportional Hazards Models; Risk Factors | 2016 |
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diagnostic Techniques, Cardiovascular; Disease Progression; Drug Combinations; Female; Gliclazide; Humans; Hypoglycemic Agents; Indapamide; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Perindopril; Pulse; Risk Factors; Stroke | 2016 |
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; Female; Gliclazide; Glycosylation; Hemoglobins; Humans; Hypoglycemic Agents; Indapamide; Male; Microcirculation; Middle Aged; Perindopril; Proportional Hazards Models; Risk; Treatment Outcome; Vascular Diseases | 2018 |
Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Intention to Treat Analysis; Male; Microvessels; Middle Aged; Perindopril; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2019 |
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow-Up Studies; Gliclazide; Humans; Hypertension; Indapamide; Life Style; Male; Middle Aged; Obesity; Overweight; Perindopril; Risk Factors; Weight Gain; Weight Loss | 2020 |
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Gliclazide; Glycated Hemoglobin; Glycemic Control; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Perindopril; Prognosis; Risk Factors; Treatment Outcome | 2020 |
8 other study(ies) available for gliclazide and perindopril
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; Female; Gliclazide; Humans; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Perindopril; Randomized Controlled Trials as Topic | 2009 |
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drug Therapy, Combination; Educational Status; Female; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Indapamide; Male; Mental Status Schedule; Myocardial Infarction; Perindopril; Risk Factors; Stroke | 2009 |
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus.
Topics: Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Combinations; Female; Gliclazide; Humans; Hypertension; Indapamide; Male; Perindopril | 2014 |
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drug Therapy, Combination; Female; Gliclazide; Health Status Indicators; Humans; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Perindopril; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2016 |
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Indapamide; Male; Middle Aged; Perindopril; Precision Medicine; Risk Factors; Risk Reduction Behavior | 2016 |
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Female; Gliclazide; Humans; Hypoglycemic Agents; Indapamide; Male; Microvessels; Middle Aged; Perindopril; Risk Factors; Treatment Outcome | 2017 |